Nadson Willian Felipe Gasparelo
Research Subjects
Research Interests
Nadson Willian Felipe Gasparelo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Adrhyan Araújo da Silva Oliveira1 shared publication
- Adriana Cristina Salvador Maia1 shared publication
- Ana Maísa Passos-Silva
Laboratório de Virologia Molecular, Fundação Oswaldo Cruz Rondônia—FIOCRUZ/RO, Porto Velho 76812-245, Brazil
1 shared publication - Camila Flávia Gomes Azzi1 shared publication
- Ciciléia Correia da Silva1 shared publication
- Deusilene Vieira
Laboratório de Virologia Molecular, Fundação Oswaldo Cruz Rondônia - FIOCRUZ/RO, Porto Velho, RO, Brazil; Programa de Pós-Graduação em Biologia Experimental, Universidade Federal de Rondônia - UNIR, Porto Velho, RO, Brazil; Centro de Pesquisa em Medicina Tropical, CEPEM, Porto Velho, RO, Brazil; Instituto Nacional de Ciência e Tecnologia de Epidemiologia da Amazônia Ocidental - INCT-EpiAmO, Porto Velho, RO, Brazil
1 shared publication
Latest Publications
- Open Access
- 28 April 2022
- Published by MDPI AG in Preprints.org
The SARS-CoV-2 Omicron Variant of Concern and its Rapid Spread throughout the Western Brazilian Amazon
Genomic surveillance represents an important strategy for understanding evolutionary mechanisms, transmission profile, and infectivity of different SARS-CoV-2 variants. We assessed the epidemiological profile of 366 individuals who tested positive for SARS-CoV-2 from 29 municipalities in Rondônia between December 2021 to March 2022. Samples were collected, RNA was ex-tracted and screened using RT-qPCR for Alpha, Beta, Gamma, Delta and Omicron VOCs and viral quantification was performed. Sequences were analyzed for phylogeny, mutations and lineages. Of the samples analyzed, 93.71% were positive for the Omicron variant and 6.28% were positive for the Delta variant. The symptoms observed were cough, sore throat, and fever, with a mean duration of 5 days; no hospitalizations or deaths were reported. We noted that among the positive individuals, 51% had been immunized with two doses, 22% received three doses, 13% received one dose, and 13% were not immunized. Just 242 samples were amenable to analysis for alignment and phylogenetic characterization; corresponding to variants BA.1 and BA.1.1; a total of 120 mutations were identified, 36% of which were found in the S gene. In conclusion, there was a high frequency of mutations in the SARS-CoV-2 genome, but no record of clinical severity, demonstrating the positive effect of vaccination.
- 28 April 2022
- Published by MDPI AG in Preprints.org
Open AccessThe SARS-CoV-2 Omicron Variant of Concern and its Rapid Spread throughout the Western Brazilian Amazon
Genomic surveillance represents an important strategy for understanding evolutionary mechanisms, transmission profile, and infectivity of different SARS-CoV-2 variants. We assessed the epidemiological profile of 366 individuals who tested positive for SARS-CoV-2 from 29 municipalities in Rondônia between December 2021 to March 2022. Samples were collected, RNA was ex-tracted and screened using RT-qPCR for Alpha, Beta, Gamma, Delta and Omicron VOCs and viral quantification was performed. Sequences were analyzed for phylogeny, mutations and lineages. Of the samples analyzed, 93.71% were positive for the Omicron variant and 6.28% were positive for the Delta variant. The symptoms observed were cough, sore throat, and fever, with a mean duration of 5 days; no hospitalizations or deaths were reported. We noted that among the positive individuals, 51% had been immunized with two doses, 22% received three doses, 13% received one dose, and 13% were not immunized. Just 242 samples were amenable to analysis for alignment and phylogenetic characterization; corresponding to variants BA.1 and BA.1.1; a total of 120 mutations were identified, 36% of which were found in the S gene. In conclusion, there was a high frequency of mutations in the SARS-CoV-2 genome, but no record of clinical severity, demonstrating the positive effect of vaccination.